Neurocrine Biosciences Inc. (NBIX) last closed at $154.06, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for NBIX, covered for search and blurred for visitors.
Performance
1D-0.49%
5D+3.97%
1M-0.66%
3M-18.86%
6M+7.72%
1Y-0.01%
5Y+36.33%
Financials
Over the latest four reported periods ending June 30, 2026, Neurocrine Biosciences Inc. reported revenue of $3.37 billion.
The prior window totaled $2.51 billion, so the latest window is higher than that stretch.
Operating cash flow in the latest window was $898.1 million.
Free cash flow in the latest window was $868 million.
These amounts are taken from Neurocrine Biosciences Inc.'s SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.
A few ratios from those statements: Profitability: ROE 3.9% (31 of 100). Cash generation: FCF margin 25.7% (51 of 100). Net margin: 15.1% (38 of 100). Liquidity: Current 1.87× (94 of 100).
Finorify's notes from those filings, written September 11, 2026: Established Market Leadership in Tardive Dyskinesia. Neurocrine has built a deep commercial moat with INGREZZA (valbenazine), a first-in-class VMAT2 inhibitor. Its established brand equity, broad prescriber network across psychiatry and neurology, and extensive patient-support infrastructure create substantial barriers to entry for potential competitors. Specialized R&D and Clinical Development Engine. The company possesses focused, proprietary expertise in neuroscience and neuroendocrinology, enabling it to advance differentiated mechanisms of action (such as crinecerfont for congenital adrenal hyperplasia and muscarinic receptor agonists) targeting underserved, high-unmet-need CNS disorders. Self-Sustaining Financial Model. Unlike early-stage biotech peers, Neurocrine generates robust operating cash flows from its commercialized portfolio, allowing the company to internally fund late-stage clinical trials, business development, and commercial launches without relying heavily on dilutive equity financing or debt. Extreme Revenue Concentration on INGREZZA. The business is heavily reliant on a single product franchise for the vast majority of its revenue and cash flow. Any emerging safety signals, label restrictions, patent challenges, or commercial slowdowns for valbenazine would severely impact the company's financial profile. Clinical Trial and Regulatory Attrition in CNS Indications. Expanding the pipeline requires navigating complex central nervous system and psychiatric clinical trials, which structurally suffer from high placebo responses, unpredictable efficacy endpoints, and rigorous regulatory scrutiny, risking significant lost R&D capital. Reimbursement and Pricing Pressures. As a specialty biopharmaceutical manufacturer, Neurocrine faces continuous scrutiny from commercial pharmacy benefit managers and government health programs (including Medicare pricing pressures), which can restrict market access through prior authorizations or demand steeper statutory rebates.
Cash Flow
Margins
Valuation
P/E (TTM)
22.56
P/S (TTM)
4.61
EV/EBITDA
18.08
Insights
Advantage
Established Market Leadership in Tardive Dyskinesia
Neurocrine has built a deep commercial moat with INGREZZA (valbenazine), a first-in-class VMAT2 inhibitor. Its established brand equity, broad prescriber network across psychiatry and neurology, and extensive patient-support infrastructure create substantial barriers to entry for potential competitors.
Advantage
Specialized R&D and Clinical Development Engine
The company possesses focused, proprietary expertise in neuroscience and neuroendocrinology, enabling it to advance differentiated mechanisms of action (such as crinecerfont for congenital adrenal hyperplasia and muscarinic receptor agonists) targeting underserved, high-unmet-need CNS disorders.
Advantage
Self-Sustaining Financial Model
Unlike early-stage biotech peers, Neurocrine generates robust operating cash flows from its commercialized portfolio, allowing the company to internally fund late-stage clinical trials, business development, and commercial launches without relying heavily on dilutive equity financing or debt.
Risk
Extreme Revenue Concentration on INGREZZA
The business is heavily reliant on a single product franchise for the vast majority of its revenue and cash flow. Any emerging safety signals, label restrictions, patent challenges, or commercial slowdowns for valbenazine would severely impact the company's financial profile.
Risk
Clinical Trial and Regulatory Attrition in CNS Indications
Expanding the pipeline requires navigating complex central nervous system and psychiatric clinical trials, which structurally suffer from high placebo responses, unpredictable efficacy endpoints, and rigorous regulatory scrutiny, risking significant lost R&D capital.
Risk
Reimbursement and Pricing Pressures
As a specialty biopharmaceutical manufacturer, Neurocrine faces continuous scrutiny from commercial pharmacy benefit managers and government health programs (including Medicare pricing pressures), which can restrict market access through prior authorizations or demand steeper statutory rebates.
Read the live analysis in Finorify
Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.